‘Growing up with values embodied by the Tatas had an immense impact on me’
Rashmi Prabhakar's uncles and cousins spent their entire careers at Tata Sons, Tata Motors, Tata Steel.
By RASHMI PRABHAKAROct 18, 2024
I WAS born into a family that was synonymous with Tata from a very young age. Born and lived in the Tata Housing Centre in Mumbai, a gated complex of 12 tower blocks, with childhood friends I am still in contact with, it is difficult to express how integral and transformative the environment was and has been throughout our childhood and upbringing.
Surrounded by hard-working, dedicated, kind and generous people, all of whom as part of the Tata family, exuded strong ethics, loyalty, respect, integrity, dignity of labour, and moral values, we also automatically adopted a similar moral compass with huge importance on people and relationships and staying true to yourself.
My uncles and cousins spent their entire careers at Tata Sons, Tata Motors, Tata Steel. My dad started his career in the 1960s at Tata Sons, Tata Consultancy Services (TCS) and then Tata Share Registry from where he retired. His entire career was devoted and dedicated to the Tatas and their growth and expansion, right until 1999 when he retired.
My dad was a family man as well as a workaholic and I can never forget how his eyes twinkled with enthusiasm and excitement as he showed me punch cards and then welcomed and set up the first IBM Supercomputer hub in TCS Chennai in the late 80s. I accompanied him many times to the pristine white air conditioned rooms with several cupboards and spinning tapes, and was so enamoured with the way people conducted themselves and the respect and camaraderie they had for each other. I realised attitude cannot be taught, only embodied and emulated.
Inspired by how his eyes lit up with passion about the work he did and the pride and humility he had in everything he did, I was truly enchanted. I did engineering in computer science, an internship in my final year at Tata Infotech, followed by my first job in August 1997, working as a software engineer for the Tatas.
Little did I know the immense impact it would have on my career and shape me into the person I am.
Ratan Tata had a vision and a purpose that was way ahead of his time, and he played a critical role in putting India on the global platform as well as doing good for others via philanthropy...
Strength and prayers to the family and everyone who is mourning his loss. Like the businesses and initiatives he built, his spirit will continue to rise, reminding us that authentic leadership is not about titles but about making a lasting, positive impact on the world. Hope we all, in some small way, are able to continue his legacy of making an impact and a difference.
Rashmi Prabhakar is head of SaaS Implementations at Temenos. She is a computer engineer and technologist, an ally and advocate for Diversity, Equity and Inclusion and an ambassador for Girls in STEM and Women in Tech. She spent her childhood in Mumbai and has been in London for over 20 years. She posted her tribute on LinkedIn.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.